Laboratory Corp. of America Holdings (NYSE:LH) had its Buy rating reiterated by Canaccord Genuity with a $200.00 price target


Analyst Ratings For Laboratory Corp. of America Holdings (NYSE:LH)

Today, Canaccord Genuity reiterated its Buy rating on Laboratory Corp. of America Holdings (NYSE:LH) with a price target of $200.00.

There are 12 Buy Ratings, 4 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Laboratory Corp. of America Holdings (NYSE:LH) is Buy with a consensus target price of $194.50 per share, a potential 3.31% upside.

Some recent analyst ratings include

  • 7/24/2018-Canaccord Genuity Reiterated Rating of Buy.
  • 7/20/2018-SunTrust Banks Reiterated Rating of Buy.
  • 6/27/2018-Deutsche Bank was Downgraded by analysts at Deutsche Bank from a “Buy ” rating to a ” Hold” rating. They now have a $172.00 price target on the stock.
  • 6/7/2018-KeyCorp Upgrade from a “Sector Weight ” rating to a ” Overweight” rating.
  • 5/25/2018-Mizuho Reiterated Rating of Hold.
  • 5/1/2018-Robert W. Baird Upgrade from a “Neutral ” rating to a ” Outperform” rating.

    About Laboratory Corp. of America Holdings (NYSE:LH)
    Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

    Recent Trading Activity for Laboratory Corp. of America Holdings (NYSE:LH)
    Shares of Laboratory Corp. of America Holdings closed the previous trading session at 188.27 up +1.33 0.71% with 186.73 shares trading hands.